Lymphoma: all 5,624 studies

Page 46 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.

• Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple MyelomaCompletedNCT00722488Phase 1
• This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.No longer availableNCT00720603
• Donor Stem Cell Transplant in Treating Patients With Mantle Cell LymphomaStatus unknownNCT00720447Phase 2
• Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT00717925Phase 1
• Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell TransplantCompletedNCT00716911Not applicable
• Health and Psychosocial Outcomes in Long-Term Lymphoma SurvivorsCompletedNCT00713882
• Educational and Skills Training Program for Parents of Childhood Cancer Survivors Who Have Neurobehavioral DysfunctionCompletedNCT00713505Not applicable
• PET Study in Patients With Non-Hodgkin LymphomaCompletedNCT00712556
• Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System LymphomaWithdrawnNCT00712062Phase 2
• Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term SurvivorsTerminatedNCT00710151
• Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell LymphomasTerminatedNCT00704691Early Phase 1
• Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/LymphomaTerminatedNCT00699296Phase 2
• Study of Oral OSI-027 in Patients With Advanced Solid Tumors or LymphomaCompletedNCT00698243Phase 1
• High-Dose Therapy Treatment in Patients With Follicular LymphomaCompletedNCT00696735Phase 3
• Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical TrialsCompletedNCT00695422
• Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00694590Phase 1
• Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins LymphomaCompletedNCT00693602Phase 1
• Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell LymphomaStatus unknownNCT00689845Not applicable
• Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell LymphomaCompletedNCT00689169Phase 2
• Fludara (Oral) Phase II Study for Indolent LymphomaCompletedNCT00688883Phase 2
• Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced CancerCompletedNCT00688415Phase 1
• Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant LymphomasCompletedNCT00685997
• Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin LymphomaCompletedNCT00678327Phase 3
• A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.CompletedNCT00677105Phase 1
• Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver FunctionCompletedNCT00674024Phase 1
• Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory LymphomaTerminatedNCT00671112Phase 1
• Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior TherapiesCompletedNCT00670592Phase 1/2
• High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell LymphomaStatus unknownNCT00669812Phase 2
• Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and RituximabCompletedNCT00667329Phase 1
• NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or LymphomaCompletedNCT00667082Phase 1
• Combination Chemotherapy in Treating Younger Patients With Hodgkin LymphomaCompletedNCT00666484Phase 2
• Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).CompletedNCT00665314Phase 2
• ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)CompletedNCT00662948Phase 2
• Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin LymphomaCompletedNCT00660231Phase 2
• Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or LymphomaCompletedNCT00659568Phase 1
• Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) LymphomaCompletedNCT00656812Phase 2
• Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCLCompletedNCT00655837Phase 1
• T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell TransplantTerminatedNCT00651716
• Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's LymphomaTerminatedNCT00651443Phase 1
• A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive MalignanciesTerminatedNCT00649584Phase 1
• Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And LymphomasCompletedNCT00647764Phase 1
• Freiburg ZNS-NHL StudyStatus unknownNCT00647049Phase 2
• Alemtuzumab and CHOP in T-cell LymphomaCompletedNCT00646854Phase 3
• KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to TreatmentCompletedNCT00646139Phase 1
• Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)CompletedNCT00644371Phase 2
• Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell LymphomaCompletedNCT00644124Phase 1
• SNX-5422 to Treat Solid Tumor Cancers and LymphomasCompletedNCT00644072Phase 1
• Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated LymphomaCompletedNCT00641381Phase 1
• Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell LymphomaCompletedNCT00641095Phase 2/3
• Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin LymphomaTerminatedNCT00637832Phase 2
• Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma.WithdrawnNCT00637117Phase 1/2
• Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's LymphomaCompletedNCT00634452Phase 1
• Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or LymphomaCompletedNCT00631579Phase 2
• A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00622258Phase 1
• Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin LymphomaCompletedNCT00621452Phase 1
• Vaccine Therapy and GM-CSF in Treating Patients With CNS LymphomaWithdrawnNCT00621036Phase 2
• Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric MalignanciesCompletedNCT00619879
• Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's LymphomaCompletedNCT00614042Phase 1
• Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell LymphomaCompletedNCT00612183Phase 2
• A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)CompletedNCT00611208Phase 2
• Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic LymphomaCompletedNCT00608374Phase 3
• Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00608361Phase 1
• Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)CompletedNCT00607854Phase 2
• Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell LymphomaCompletedNCT00606645Phase 1
• T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic CancerCompletedNCT00602693Phase 1
• Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaCompletedNCT00599170Phase 2
• Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)Status unknownNCT00598624Phase 2
• Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin LymphomaCompletedNCT00598169Phase 1
• Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's LymphomaCompletedNCT00596804Phase 1/2
• Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and LymphomasCompletedNCT00592163Phase 1
• Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell LymphomaCompletedNCT00590941Not applicable
• Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or LymphomaCompletedNCT00589381Phase 1
• A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00587015Phase 1
• Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell LymphomaCompletedNCT00586755Phase 2
• R-CHOP + GM-CSF for Previously Untreated LCL in ElderlyCompletedNCT00582725Phase 2
• Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent LymphomaCompletedNCT00582270
• Cognitive Functioning and Quality of Life in CNS LymphomaCompletedNCT00581737
• Prevalence of Lymphoma in IBDCompletedNCT00577538
• Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHLWithdrawnNCT00577161Phase 3
• Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell LymphomaCompletedNCT00575406Phase 2
• Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's LymphomaCompletedNCT00575068Phase 1/2
• Idiotype Vaccine After Chemotherapy & Stem Cell Transplantation in Lymphoma With Failed Induction ChemotherapyCompletedNCT00574886Not applicable
• CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's LymphomaCompletedNCT00574730Not applicable
• Comparing Autologous Peripheral Blood Stem Cell to Bone Marrow Transplantation for Recurrent Non-Hodgkin's LymphomaCompletedNCT00574626Not applicable
• Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's LymphomaCompletedNCT00574509Phase 1
• Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's LymphomasCompletedNCT00572637Phase 1
• Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent LymphomaCompletedNCT00572013Phase 1/2
• Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related LymphomaCompletedNCT00569985Phase 1
• Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT00568815Phase 2
• Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell LymphomaStatus unknownNCT00568607Phase 2
• Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström MacroglobulinemiaCompletedNCT00566332Phase 3
• AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin LymphomaCompletedNCT00562380Phase 1
• Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell LymphomaStatus unknownNCT00562068Phase 1
• Vaccine Therapy in Treating Patients With Recurrent B-Cell LymphomaCompletedNCT00561756Phase 1
• Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-RituximabCompletedNCT00561379Not applicable
• Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant LymphomaStatus unknownNCT00561301Phase 2
• Study of RH-1 in Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaTerminatedNCT00558727Phase 1
• A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological MalignancyCompletedNCT00558675Phase 1/2
• R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell LymphomasCompletedNCT00558220Phase 2
• A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's LymphomaCompletedNCT00556699Phase 1

← Lymphoma overview